DiaMedica Therapeutics Inc. (DMAC) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts DMAC Hot Sheet
Join SI Premium – FREE
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16).
For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
- Nocera files to register 7.5 million shares under SEC Form S-3
- Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
